Active substance
Somatostatin
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SOMATOSTATIN-UCB250MCG LYOP.VIAL+SOLVENT | 250 µg | Solution · Intravenous use | 1 Vial | SAR 63.55 | Biological · Prescription | U.C.B. | Withdrawn by MAH · Not Marketed |
| SOMATOSTATINE-UCB 3MG LYOP.VIAL+SOLVENT | 3 mg | Solution · Intravenous use | 1 Vial | SAR 498.40 | Biological · Prescription | U.C.B. | Withdrawn by MAH · Not Marketed |
| STILAMIN 250MCG AMP+SOLVENT | 250 µg | Injection · Intravenous use | 1 Ampoule | SAR 66.10 | Biological · Prescription | SERONO | Withdrawn by MAH · Not Marketed |
| STILAMIN 3MG AMP+SOLVENT | 3 mg | Injection · Intravenous use | 1 Ampoule | SAR 475.20 | Biological · Prescription | SERONO | Withdrawn by MAH · Not Marketed |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.